Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA cosponsors health policy conference series

Executive Summary

Rising rates of chronic medical conditions is the topic of a July 31 conference convened by the Center for Studying Health System Change and sponsored by the Pharmaceutical Research and Manufacturers of America, the American College of Preventive Medicine and DMAA: The Care Continuum Alliance. Chronic illness was the theme of PhRMA's most recent annual meeting (1"The Pink Sheet," April 7, 2008, p. 15). The upcoming session, to be held in Washington, D.C. will consider the growing prevalence of chronic health conditions, and resulting costs, consequences and need for preventive strategies. It is the first of four policy conferences; future topics include value-based health benefit structures

You may also be interested in...



PhRMA Annual Meeting’s Message: Stand Tall, But Gaze Past Your Navel

DANA POINT, Calif. - A mood of resolute pride saturated the 50th annual meeting of the Pharmaceutical Research and Manufacturers of America, where speakers and panelists stressed the industry's eventual return to its once-bright public image by spreading the news about what they said is the biggest factor pushing up costs of medical care in the developed world: treatment of chronic diseases, especially those caused by obesity

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel